Coronavirus disease 2019 (COVID‐19) has been spreading worldwide with a mind-boggling speed. According to a statement from World Health Organization (WHO), COVID-19 has infected more than six billions people and caused more than one and half million passing in the world. Based on previous experience with SARS, the Taiwanese government had decided to block viral transmission during its early stages. This review sums up the clinical characteristics, Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) viral infection process, diagnostic methods, preventive strategy, and the executive proportions of COVID-19, as well as the name-based mask distribution system (NBMDS) in Taiwan. We also give a review of the conceivable sub-atomic pharmacologic systems against SARS-CoV-2 specialists and the blend of remdesivir (GS-5734), chloroquine (CQ), and hydroxychloroquine (HCQ). Lastly, we summarized the therapeutic agents against COVID-19 as mentioned by COVID-19 treatment guidelines. In this review, development of novel anti-SARS-CoV-2 viral agents, vaccines for COVID-19 therapy or an effective combination therapy can be expected based on all the information accumulated. Last but not least, we might want to stretch out our best respects to all medical providers in their worldwide battle against COVID-19.
Chiu, Yu-Jen; Chiang, Jo‑Hua; Fu, Chih-Wei; Hour, Mann-Jen; Ha, Hai-Anh; Kuo, Sheng-Chu; Lin, Jen-Jyh; Cheng, Ching-Chang; Tsai, Shih‑Chang; Lo, Yu‑Shiang; Juan, Yu‑Ning; Cheng, Yih-Dih; Yang, Jai-Sing; and Tsai, Fuu‑Jen
"Analysis of COVID-19 prevention and treatment in Taiwan (Review),"
BioMedicine: Vol. 11
, Article 1.
Cover letters-20210111.docx (13 kB)
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.